Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide in clinical practice: pooled 12-month results from the global BICSTaR study

被引：0
|
作者：
Spinner, C. [1 ]
Stoehr, A. [2 ]
Wong, A. [3 ]
de Wet, J. [4 ]
Zeggagh, J. [5 ]
Hocqueloux, L. [6 ]
van Welzen, B. [7 ]
Heinzkill, M. [8 ]
Sahali, S. [9 ]
Cornejo, A. Torres [10 ]
Ramroth, H. [11 ]
Haubrich, R. [12 ]
Thorpe, D. [13 ]
Kim, C. [14 ]
机构：
[1] Tech Univ Munich, Univ Hosp Rechts Isar, Sch Med, Munich, Germany
[2] IFI Studien & Projekte GmbH, Zentrum Infektiol, Hamburg, Germany
[3] Univ Saskatchewan, Dept Med, Regina, SK, Canada
[4] Spectrum Hlth, Vancouver, BC, Canada
[5] Hop St Louis, AP HP, Serv Malad Infect, Paris, France
[6] CHR Orleans, Serv Malad Infect & Trop, Orleans, France
[7] Univ Med Ctr, Internal Med & Infect Dis, Utrecht, Netherlands
[8] Gilead Sci GmbH, HIV Med Affairs, Munich, Germany
[9] Gilead Sci, HIV Med Affairs, Paris, France
[10] Gilead Sci Netherlands BV, HIV Med Affairs, Amsterdam, Netherlands
[11] Gilead Sci Ltd, Pharmacovigilance & Epidemiol, London, England
[12] Gilead Sci Inc, Med Affairs Res, 353 Lakeside Dr, Foster City, CA 94404 USA
[13] Gilead Sci Europe Ltd, HIV Med Affairs, London, England
[14] Gilead Sci Canada Inc, HIV Med Affairs, Mississauga, ON, Canada
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P046
引用
收藏
页码：50 / 51
页数：2
相关论文
共 50 条
  • [41] Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in HIV-suppressed patients
    Cicalini, S.
    Lorenzini, P.
    Grilli, E.
    Plazzi, M. M.
    De Zottis, F.
    Camici, M.
    Fusto, M.
    Gagliardini, R.
    Bellagamba, R.
    Antinori, A.
    HIV MEDICINE, 2021, 22 : 31 - 32
  • [42] 24-Month (24M) effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive (TN) and treatment-experienced (TE) people living with HIV in the BICSTaR study
    Garcia-Deltoro, Miguel
    Waizmann, Michael
    Robineau, Olivier
    Wong, Alexander
    Shahar, Eduardo
    Lambert, John S.
    van Welzen, Berend
    Boffito, Marta
    Yokomaku, Yoshiyuki
    Cassidy, Tali
    Marongiu, Andrea
    Thorpe, David
    Heinzkill, Marion
    Lluis-Ganella, Carla
    Di Perri, Giovanni
    HIV MEDICINE, 2023, 24 : 23 - 23
  • [43] Associations with weight change and patient-reported outcomes after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
    Lowman, E.
    Unger, N.
    Hardigan, P. C.
    Lee, N.
    HIV MEDICINE, 2020, 21 : 20 - 20
  • [44] Switching to bictegravir/emtricitabine/tenofovir alafenamide in adults aged >65 years or older: Week 72 results from an international, phase IIIb, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J.
    Pulido, F.
    De Wit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    Haubrich, R.
    McNicholl, I.
    Gallant, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 43 - 44
  • [45] Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients
    Gutierrez-Lorenzo, Marta
    Rubio-Calvo, Daniel
    Urda-Romacho, Joaquin
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2021, 34 (04) : 315 - 319
  • [46] Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice
    Armenia, Daniele
    Forbici, Federica
    Bertoli, Ada
    Berno, Giulia
    Malagnino, Vincenzo
    Gagliardini, Roberta
    Borghi, Vanni
    Gennari, William
    Cicalini, Stefania
    Buonomini, Annarita
    Teti, Elisabetta
    Lanini, Simone
    Latini, Alessandra
    Sarmati, Loredana
    Mussini, Cristina
    Andreoni, Massimo
    Antinori, Andrea
    Perno, Carlo F.
    Ceccherini-Silberstein, Francesca
    Santoro, MariaM.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 30 : 326 - 334
  • [47] The effects of switching from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study
    Rossetti, B.
    Ferrara, M.
    Taramasso, L.
    Bai, F.
    Lombardi, F.
    Ciccarelli, N.
    Durante, M.
    Alladio, F.
    Rancan, I.
    Montagnani, F.
    Di Biagio, A.
    Monforte, A. d'Arminio
    Zazzi, M.
    Fabbiani, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 161 - 162
  • [48] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
    Hagins, Debbie
    Kumar, Princy
    Saag, Michael
    Wurapa, Anson K.
    Brar, Indira
    Berger, Daniel
    Osiyemi, Olayemi
    Hileman, Corrilynn O.
    Ramgopal, Moti N.
    McDonald, Cheryl
    Blair, Christiana
    Andreatta, Kristen
    Collins, Sean E.
    Brainard, Diana M.
    Martin, Hal
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (01) : 86 - 95
  • [49] Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
    Ranzenigo, Martina
    Gianotti, Nicola
    Galli, Laura
    Poli, Andrea
    Mastrangelo, Andrea
    Bruzzesi, Elena
    Chiurlo, Matteo
    Nozza, Silvia
    Bossolasco, Simona
    Spagnuolo, Vincenzo
    Mancusi, Daniela
    Termini, Roberta
    Carini, Elisabetta
    Lazzarin, Adriano
    Castagna, Antonella
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 1975 - 1982
  • [50] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F
    Acosta, R.
    Andreatta, K.
    D'Antoni, M.
    Collins, S.
    Martin, H.
    White, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 106 - 106
12345